KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor antibody in metastatic colorectal cancer (CRC). KRAS mutation analysis is usually performed on primary tumour tissue because metastatic tissue is often not available. However, controver...

Descripción completa

Detalles Bibliográficos
Autores principales: Knijn, N, Mekenkamp, L J M, Klomp, M, Vink-Börger, M E, Tol, J, Teerenstra, S, Meijer, J W R, Tebar, M, Riemersma, S, van Krieken, J H J M, Punt, C J A, Nagtegaal, I D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065268/
https://www.ncbi.nlm.nih.gov/pubmed/21364579
http://dx.doi.org/10.1038/bjc.2011.26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065268/
https://www.ncbi.nlm.nih.gov/pubmed/21364579
http://dx.doi.org/10.1038/bjc.2011.26

Ejemplares similares